Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.
| Revenue (Most Recent Fiscal Year) | $85.23M |
| Net Income (Most Recent Fiscal Year) | $3.19M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 131.86 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.76 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.93 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 176.57 |
| Pre-Tax Margin (Trailing 12 Months) | 4.12% |
| Net Margin (Trailing 12 Months) | 3.17% |
| Return on Equity (Trailing 12 Months) | 2.63% |
| Return on Assets (Trailing 12 Months) | 2.39% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.92 |
| Quick Ratio (Most Recent Fiscal Quarter) | 13.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.15 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Year) | $0.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.07 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 34.75M |
| Free Float | 28.70M |
| Market Capitalization | $320.71M |
| Average Volume (Last 20 Days) | 0.52M |
| Beta (Past 60 Months) | 0.38 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.12% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |